Clinical trials: Hepatobiliary Disorders
Non-alcoholic Fatty Liver Disease (NAFLD), Omega-3 Supplementation
Effectiveness of Nutrition Education Program and Omega-3 Supplementation Among Non-alcoholic Fatty Liver Disease Patients
The aim of this clinical trial is to examine the impact of nutritional education and omega-3 supplementation in influencing body weight, liver enzyme levels, and lipid profiles in patients diagnosed with non-alcoholic fatty liver…
- Conditions
- Non-alcoholic Fatty Liver Disease (NAFLD), Omega-3 Supplementation, Nutrition Education Program
- Trial name
- NCT06627114
- Testing
- nutrition education program, Omega 3 fatty acids, control group
- Where
- Iraq
- Volunteers
- 159 people
- Sponsor
- Hawler Medical University
Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)
This randomized, double-blind, placebo-controlled Phase II study evaluates whether daily subcutaneous tesamorelin (a growth hormone-releasing hormone analog) reduces liver fat in adults with fatty liver disease.
- Conditions
- Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis, Hepatic Steatosis
- Trial name
- TESA-LIVER (NCT07481734)
- Testing
- Tesamorelin, Standardized lifestyle counseling
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Hudson Biotech
Liver Diseases, Alcoholic, Fibrosis
Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers
Prospective screening study at Odense University Hospital to assess the effect of transient elastography and other serum and imaging markers of liver fibrosis to detect advanced fibrosis (Kleiner Fibrosis score F3-F4) in patients…
- Trial name
- SIPHON (NCT03308916)
- Testing
- transient elastography, Enhanced liver fibrosis test, Indirect serum markers of liver fibrosis
- Where
- Denmark
- Volunteers
- 6,500 people
- Sponsor
- Maja Thiele
Morbid Obesity, Non-alcoholic Fatty Liver Disease
Effect of Macrocomposition on Nonalcoholic Fatty Liver Disease (NAFLD) in Bariatric Surgery Candidates
Nonalcoholic Liver disease (NAFLD) is known to be caused by deposition of fat in the liver. The impact of NAFLD on bariatric surgery is of great concern.
- Trial name
- NCT00887393
- Testing
- low carbohydrate diet, low-fat diet
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Michigan
NASH - Nonalcoholic Steatohepatitis
Interest in "Combo" (a Combination of Dietary Supplements Including Probiotics) in NASH Improvement
The aim of this bicentre, prospective, placebo-controlled, double-blind, randomized, interventional study is to assess for the first time the effects of a Combo with probiotics and dietary supplements compared to placebo for…
- Trial name
- ICAN (NCT04781933)
- Testing
- Treatment with Combo
- Where
- 2 sites in France
- Volunteers
- 60 people
- Sponsor
- Mativa-Tech SA
Liver Disease
Comparing Pain in Patients Undergoing Percutaneous Versus Transjugular Techniques of Liver Biopsy
Background: In a liver biopsy, a small piece of liver is removed. A percutaneous liver biopsy (PLB) is done through a needle on the right side of your belly.
- Trial name
- NCT02311348
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Liver Fibrosis/NASH
Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.
Metabolic dysfunction-associated steatotic liver disease (MASLD) (aka non-alcoholic fatty liver disease), commonly occurring in individuals with obesity and type 2 diabetes can lead to liver inflammation/ fibrosis.
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Liver Fibrosis/NASH, Non-Alcoholic Steato-Hepatitis (NASH)
- Trial name
- AGL13 (NCT06843148)
- Testing
- Niacin (250mg)
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- Université de Sherbrooke
Non-Alcoholic Fatty Liver Disease
Ursodeoxycholic Acid in Patients With NAFLD - Clinical Observation
Patients with NAFLD indicated for ursodeoxycholic acid treatment ("by SPC: cholestatic hepatitis") will be offered an observational study. Examinations will be performed before the treatment and after 6month period.
- Trial name
- URSO (NCT05256979)
- Where
- Czechia
- Volunteers
- 20 people
- Sponsor
- General University Hospital, Prague
Coronary Disease, Coronary Arteriosclerosis
Effects of a Healthy Nordic Diet on Atherosclerosis in Patients with Coronary Heart Disease
Diet can play a key role in atherosclerosis and coronary heart disease (CHD), but little interventional data exists, and the mediators of possible anti-atherosclerotic effects of diet are unclear.
- Conditions
- Coronary Disease, Coronary Arteriosclerosis, Myocardial Infarction, Chronic Coronary Syndrome
- Trial name
- NORDHEART (NCT06701968)
- Testing
- Healthy Nordic Diet, Usual Care
- Where
- Sweden
- Volunteers
- 150 people
- Sponsor
- Uppsala University
Upper Gastrointestinal Disorders, Lower Gastrointestinal Disorders
Sarcopenia and Physiology Assessments in Cancer Patients
Primary Aim: To establish a reliable relationship between oxygen uptake (VO2) at estimated lactate threshold (AT) and CT-derived body composition measurments (e.g.
- Conditions
- Upper Gastrointestinal Disorders, Lower Gastrointestinal Disorders, Hepatobiliary Cancer
- Trial name
- NCT03641118
- Testing
- Cardiopulmonary exercise test
- Where
- United Kingdom
- Volunteers
- 639 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Chronic Liver Disease
Effect of BCAA Supplementation on Muscle Mass, Muscle Quality and Molecular Markers of Muscle Regeneration in CLD Patients
Loss of muscle mass (sarcopenia) is a major complication in a patient with cirrhosis, impacting the disease outcome, quality of life and survival.
- Trial name
- BCAA-CLD (NCT04246918)
- Testing
- Branched Chain Amino Acid, Whey Protein concentrate powder
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Non-Alcoholic Fatty Liver Disease
Determination of the Effect of Extreme Dietary Carbohydrate Restriction on Hepatic Glucose Production
All subjects will be evaluated by the Research Nurse at the Clinical Translational Research Center (CTRC) Outpatient Clinic to obtain informed consent, a brief medical history, weight, body mass index, waist/hip circumference and…
- Trial name
- NCT01262326
- Testing
- Calorie and Carbohydrate Restriction
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes
HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes
A phase 2b, multicenter, randomized, double-blind, placebo-controlled study of HTD1801 in adult subjects with non-alcoholic steatohepatitis and liver fibrosis who have type 2 diabetes mellitus or pre-diabetes.
- Trial name
- CENTRICITY (NCT05623189)
- Testing
- HTD1801
- Where
- 45 sites in United States, Hong Kong and 1 more
- Volunteers
- 218 people
- Sponsor
- HighTide Therapeutics (Hong Kong) Limited
Nonalcoholic Fatty Liver Disease, Dyslipidemias
Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease
To investigate the therapeutic effect of ezetimibe on nonalcoholic fatty liver disease, the effect of rosuvastatin 5mg monotherapy and rosuvastatin 5mg / ezetimibe 10mg combination therapy n patients with hyperlipidemia and fatty…
- Trial name
- NCT03434613
- Testing
- Rosuvastatin, Rosuvastatin/ezetimibe combination
- Where
- South Korea
- Volunteers
- 64 people
- Sponsor
- Yonsei University
Metabolic Dysfunction-associated Steatotic Liver Disease
Targeting the Skeletal Muscle to Treat Metabolic Dysfunction-associated Steatotic Liver Disease
Muscle changes including myosteatosis are reported as highly prevalent in metabolic dysfunction-associated steatotic liver disease (MASLD). Recent studies highlighted a link between muscle fat content and liver disease severity.
- Trial name
- MYO-MASLD (NCT06506513)
- Testing
- High-intensity interval training, Moderate intensity exercise training, Low intensity exercise training
- Where
- 2 sites in Belgium
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue
Obesity and type 2 Diabetes Mellitus prevalence has doubled in the last 30 years and nearly one fifth of UAE population has Type 2 Diabetes while more than quarter has obesity.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Type 2 Diabetes, Liver Fat
- Trial name
- NCT05751720
- Testing
- GIP/GLP-1a
- Where
- United Arab Emirates
- Volunteers
- 30 people
- Sponsor
- Dr Adnan Agha
Diabetes Mellitus, Type 2
A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People With Liver Disease
Participants will receive one insulin icodec dose, which will be administered in the morning of the day of dosing. The study will last for about 8 weeks.
- Trial name
- NCT04597697
- Testing
- Insulin icodec
- Where
- 2 sites in Czechia, Slovakia
- Volunteers
- 25 people
- Sponsor
- Novo Nordisk A/S
Cholestasis, Liver Disease
Enteral Fish Oil is Superior to Ursodeoxycholic Acid (UDCA) and Placebo for the Treatment of Cholestasis in Infants
To investigate the effect of enteral fish oil and UDCA on the time of cholestasis resolution and other markers of parenteral nutrition-associated liver disease.
- Trial name
- NCT02420496
- Testing
- Enteral fish oil, Ursodeoxycholic Acid
- Where
- United States
- Sponsor
- The University of Texas Health Science Center at San Antonio
Chronic Liver Disease
The SHUNT-V Study for Varices
The purpose of this study is to validate the Disease Severity Index (DSI) from the HepQuant SHUNT Liver Diagnostic Kit (Test) for likelihood of large esophageal varices.
- Trial name
- NCT03583996
- Testing
- HepQuant SHUNT Liver Diagnostic Test
- Where
- 26 sites in United States
- Volunteers
- 306 people
- Sponsor
- HepQuant, LLC
Zhejiang University
Split or Whole Liver Transplantation? A Multicenter Retrospective Cohort Study of Patients With Benign and Malignant Liver Disease
The primary objective of this study was to assess the safety and feasibility of split liver transplantation(SLT) for adult hepatocellular carcinoma (HCC) patients, while comparing the prognostic disparities between adult SLT and…
- Trial name
- NCT06359496
- Testing
- No intervention factor
- Where
- China
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Zhejiang University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.